Aptose Biosciences Inc. (NASDAQ: APTO) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $5.00 price target on the stock.
Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.
Aptose Reports Results for the Fourth Quarter and Full Year 2023 [Yahoo! Finance]